Zealand Pharma A/S Establishes New Scientific Committee, Which Will Comprise of Kirsten Aarup Drejer as the Chair, Michael John Owen and Alain Munoz as Members of the Committee

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.